Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

NCT02692742 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-Induced Neutropenia
Myelosuppression
Breast Cancer

Interventions

DRUG: Myelo001
DRUG: Placebo

Sponsor

Myelo Therapeutics GmbH